These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 15974638)

  • 21. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD.
    Jenner P
    Neurology; 2003 Dec; 61(11 Suppl 6):S32-8. PubMed ID: 14663007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical/pharmacological aspect of adenosine A2A receptor antagonist for dyskinesia.
    Kanda T; Uchida S
    Int Rev Neurobiol; 2014; 119():127-50. PubMed ID: 25175964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
    Hauser RA; Hubble JP; Truong DD;
    Neurology; 2003 Aug; 61(3):297-303. PubMed ID: 12913187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-parkinsonian activity of the adenosine A
    Ohno Y; Okita E; Kawai-Uchida M; Fukuda N; Shoukei Y; Soshiroda K; Yamada K; Kanda T; Uchida S
    Eur J Pharmacol; 2023 Jul; 950():175773. PubMed ID: 37146707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can adenosine A
    Kanda T; Jenner P
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S21-S27. PubMed ID: 33349576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Pharmacological Potential of Adenosine A
    Mori A; Chen JF; Uchida S; Durlach C; King SM; Jenner P
    Molecules; 2022 Apr; 27(7):. PubMed ID: 35408767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.
    Pourcher E; Fernandez HH; Stacy M; Mori A; Ballerini R; Chaikin P
    Parkinsonism Relat Disord; 2012 Feb; 18(2):178-84. PubMed ID: 22000279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
    Jenner P; Mori A; Hauser R; Morelli M; Fredholm BB; Chen JF
    Parkinsonism Relat Disord; 2009 Jul; 15(6):406-13. PubMed ID: 19446490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A
    Ohno Y; Suzuki M; Asada H; Kanda T; Saki M; Miyagi H; Yasunaga M; Suno C; Iwata S; Saito JI; Uchida S
    Mol Pharmacol; 2023 Jun; 103(6):311-324. PubMed ID: 36894319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of istradefylline for Parkinson's disease: A systematic review and meta-analysis.
    Wang XL; Feng ST; Chen B; Hu D; Wang ZZ; Zhang Y
    Neurosci Lett; 2022 Mar; 774():136515. PubMed ID: 35149201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
    Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
    Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the adenosine A
    Zhao Y; Zhou YG; Chen JF
    Chin J Traumatol; 2024 May; 27(3):125-133. PubMed ID: 37679245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of istradefylline on non-motor symptoms of Parkinson's disease: A subanalysis of a 1-year observational study in Japan (J-FIRST).
    Shimo Y; Maeda T; Chiu SW; Yamaguchi T; Kashihara K; Tsuboi Y; Nomoto M; Hattori N; Watanabe H; Saiki H;
    Parkinsonism Relat Disord; 2021 Oct; 91():115-120. PubMed ID: 34583302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of istradefylline for Parkinson's disease: A meta-analysis.
    Sako W; Murakami N; Motohama K; Izumi Y; Kaji R
    Sci Rep; 2017 Dec; 7(1):18018. PubMed ID: 29269791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of adenosine A
    Pinna A; Serra M; Morelli M; Simola N
    J Neural Transm (Vienna); 2018 Aug; 125(8):1273-1286. PubMed ID: 29396609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and effectiveness of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing surveillance study in Japan.
    Takahashi M; Fujita M; Asai N; Saki M; Mori A
    Expert Opin Pharmacother; 2018 Oct; 19(15):1635-1642. PubMed ID: 30281377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can adenosine A
    Jenner P; Mori A; Kanda T
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S28-S36. PubMed ID: 33349577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of oral adenosine A(2A) antagonist istradefylline for the treatment of moderate to severe Parkinson's disease.
    Vorovenci RJ; Antonini A
    Expert Rev Neurother; 2015; 15(12):1383-90. PubMed ID: 26630457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety of istradefylline for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Drug Saf; 2015 May; 14(5):769-75. PubMed ID: 25676023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The challenge of developing adenosine A
    LeWitt PA; Aradi SD; Hauser RA; Rascol O
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S54-S63. PubMed ID: 33349581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.